Synthesis of doxorubicin conjugates through 14-hydroxy group to melanotransferrin p97

Synthetic Communications

Volumn 33, Issue 14, 2003, Pages 2391-2400

  Chen, Qingqi ^a   Sowa, Damian A ^a   Gabathuler, Reinhard ^a  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Anticancer drug; Bioconjugate; Blood brain barrier; Brain tumor; Cross linking; Doxorubicin; Drug delivery; Ester bond linkage; Protein carrier

Indexed keywords

9 FLUORENYLMETHYL N SUCCINIMIDYLCARBONATE; AMINO ACID; CARBONIC ACID DERIVATIVE; DOXORUBICIN; GLUTARIC ACID; HYDROXYL GROUP; MELANOTRANSFERRIN P97; SUCCINIC ACID; TRANSFERRIN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; COVALENT BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; HUMAN;

EID: 0042564733     PISSN: 00397911     EISSN: None     Source Type: Journal    
DOI: 10.1081/SCC-120021828     Document Type: Article

References (27)

1. Arcamone, F. Doxorubicin Anticancer Antibiotics; Academic Press: New York, 1981; chapter 2.
2. Wiernik, P.H. Anthracyclines. Current Status and New Developments; Crooke, S.T., Reich, S.D., Eds.; Academic Press: New York, 1980; pp. 273-294.
3. Dorr, R.T.; Von Hoff, D.D. Cancer Chemotherapy Handbook, 2nd Ed.; Appleton and Lange: New York, 1994.
4. Begley, D.J.; Bradbury, M.W.; Kreuter, J. The Blood-Brain Barrier and Drug Delivery to the CNS; Marcel Dekker, Inc.: New York, 2000.
5. (a) Fratz, F.; Beyer, U.; Roth, T.; Tarasova, N.; Collery, P.; Lechenault, F.; Cazabat, A.; Schumacher, P.; Unger, C.; Falken, U. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake. J. Pharm. Sci. 1998, 87 (3), 338-346;
6. (b) King, D.H.; Yurgaitis, D.; Willner, D.; Firestone, R.A.; Yang, M.B.; Lasch, S.J.; Hellstron, K.E.; Trail, P.A. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates. Bioconjugate Chem. 1999, 10 (2), 279-288.
7. (a) Lau, A.; Berube, G.; Ford, C.H.J. Conjugation of doxorubicin to monoclonal anticarcinoembryonic antigen antibody via novel thio-directed cross-linking reagents. Bioorg. Med. Chem. 1995, 3 (10), 1299-1304;
8. (b) Froesch, B.A.; Stahel, R.A.; Zangemeister-Wittke, U. Preparation and funtional evaluation of new doxorubicin immunoconjugates containing and acid-sensitive linker on small-cell lung cancer cells. Cancer Immunol. Immunother. 1996, 42 (1), 55-63.
9. (a) Godwin, A.; Hartenstein, M.; Muller, A.H.E.; Brocchini, S. Narrow molecular weight distribution precursors for polymer-drug conjugates. Angew. Chem. Int. Ed. 2001, 40 (3), 594-597;
10. (b) Yokoyama, M.; Fukushima, S.; Uehara, R.; Okamoto, K.; Kataoka, K.; Sakurai, Y.; Okano, T. Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J. Control. Release 1998, 50 (1), 79-92;
11. (c) Nogusa, H.; Yano, T.; Kashima, N.; Yamamoto, K.; Okuno, S.; Hamana, H. Structure-activity relationships of carboxymethylpullulan-peptide-doxorubicin conjugates - systematic modification of peptide spacer. Bioorg. Med. Chem. Lett. 2000, 10 (3), 227-230;
12. (d) Dvorak, M.; Kopeckova, P.; Kopecek, J. High-molecular weight HMPA copolymer-adriamycin conjugates. J. Control. Release 1999, 60 (3), 321-332;
13. (e) Rodrigues, P.C.A.; Beyer, U.; Schumacher, P.; Roth, T.; Fiebig, H.H.; Unger, C.; Messori, L.; Orioli, P.; Paper, D.H.; Mulhaupt, R.; Kratz, F. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorg. Med. Chem. 1999, 7 (11), 2517-2524.
14. (a) Dubowchik, G.M.; Firestone, R.A. Capthepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8 (23), 3341-3346;
15. (b) Dubowchik, G.M.; Mosure, K.; Knipe, J.O.; Firestone, R.A. Capthepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs pacitaxel (Taxol), mitomycin C and doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8 (23), 3347-3352.
16. Garnett, M.C. Targeted drug conjugates: principles and progress. Adv. Drug Delivery Rev. 2001, 53 (2), 171-216.
17. (a) Rousselle, C.; Clair, P.; Lefauconnier, J.-M.; Kaczorek, M.; Scherrmann, J.-M. Temsamani, J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 2000, 57 (4), 679-686;
18. (b) Remsen, L.G.; Trail, P.A.; Hellstrom, I.; Hellstrom, K.E.; Neuwelt, E.A. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 2000, 46 (3), 704-709.
19. (a) Yamada, T.; Tsujioka, Y.; Taguchi, J.; Takahashi, M.; Tsuboi, Y.; Moroo, I.; Yang, J.; Jefferies, W. A. Brain Research 1999, 845 (1), 1-5;
20. (b) Rothenberger, S.; Food, M.R.; Gabthuler, R.; Kennard, M.L.; Yamada, T.; Yasuhara, O.; McGeer, P.L.; Jefferies, W.A. Brain Research 1996, 712 (1), 117-121.
21. Chen, Q.; Sowa, D.; Cai, L.J. Gabathuler, R. Efficient one-pot synthesis of doxorubicin conjugates through its amino group to melanotransferrin p97. Synth. Commun. 2003, 33 (14), 2399-2419.
22. Chen, Q.; Sowa, D.; Gabathuler, R. Synthesis of doxorubicin conjugates through hydrazone bonds to melanotransferrin p97. Synth. Commun. 2003, 33 (14), 2375-2388.
23. Tanaka, H.; Komintao, K.; Yoshioka, T.; Iguchi, H.; Hirano, S.I.; Okajima, Y.; Yamamoto, R.; Shirai, M.; Nishida, H.; Tone, H.; Okamoto, R. Conjugate of Adriamycin and Cyclodextrin. US. Patent 5,183,883, February 2, 1993.
24. (a) Nagy, A.; Schally, A.V.; Halmos, G.; Armatis, P.; Cai, R.Z.; Csernus, V.; Kovacs, M.; Koppan, M.; Szepeshazi, K. Synthesis and biological evaluation of cytoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolino-doxorubicin. Proc. Natl. Acad. Sci. USA 1998, 95 (4), 1794-1799;
25. (b) Nagy, A.; Schally, A.V.; Armatis, P.; Szepeshazi, K.; Halmos, G.; Kovacs, M.; Zarandi, M.; Groot, K.; Miyazaki, M.; Jungwrith, A.; Horvath, J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc. Natl. Acad. Sci. USA 1996, 93 (14), 7269-7273;
26. (c) Nagy, A.; Armatis, P.; Cai, R.Z.; Szepeshazi, K.; Halmos, G.; Schally, A.V. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like, peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolino-doxorubicin. Proc. Natl. Acad. Sci. USA 1997, 94 (2), 625-656.
27. Green, T.W.; Wuts, P.G.M. Protective Groups in Organic Synthesis, 3rd Ed.; John Wiley & Sons, Inc.: New York, 1999; 506-507.